Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.67 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.66 |
| ▸ | BCHE | P06276 | 3/20 | 0.62 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.62 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137838 | 0.98 | MRGPRX4 (0.69) | MAOBMRGPRX4BCHECYP4F2CYP4A11 | |
| SCHEMBL16346074 | 0.93 | GSTP1 (0.66) | MAOBMRGPRX4BCHECYP4F2CYP4A11 | |
| SCHEMBL12635690 | 0.89 | MAOB (0.60) | MAOBMRGPRX4BCHECYP4F2CYP4A11 | |
| SCHEMBL12746077 | 0.89 | MAOB (0.81) | MAOBMRGPRX4BCHECYP4F2CYP4A11 | |
| SCHEMBL7346174 | 0.89 | MRGPRX4 (0.64) | MAOBMRGPRX4BCHECYP4F2CYP4A11 | |
| SCHEMBL3787907 | 0.89 | MAOB (0.81) | MAOBMRGPRX4BCHECYP4F2CYP4A11 | |
| SCHEMBL26830356 | 0.89 | MAOB (0.58) | MAOBMRGPRX4BCHECYP4F2CYP4A11 | |
| SCHEMBL1268719 | 0.89 | MAOB (0.81) | MAOBBCHECYP4F2CYP4A11NR4A2 | |
| SCHEMBL2570119 | 0.88 | MAOB (0.65) | MAOBMRGPRX4BCHECYP4F2CYP4A11 | |
| SCHEMBL1956583 | 0.88 | MRGPRX4 (0.58) | MAOBMRGPRX4BCHECYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| EP-2181174-B1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2181174-A1 | LIQUID CRYSTAL DISPLAY | Merck Patent GmbH (DE) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009030322-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | KLK3, LPXN, PSAP | MAOB 3582/4885MRGPRX4 3808/4885BCHE 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.